PMID- 31275298
OWN - NLM
STAT- MEDLINE
DCOM- 20201022
LR  - 20220727
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 10
DP  - 2019
TI  - Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
PG  - 1238
LID - 10.3389/fimmu.2019.01238 [doi]
LID - 1238
AB  - Bullous pemphigoid (BP) is an organ-specific autoantibody-mediated blistering 
      skin disease that mainly affects the elderly. Typical clinical features include 
      the widespread blisters, often preceded by and/or associated with itchy 
      urticarial or eczema-like lesions. BP patients have circulating autoantibodies 
      against BP180 and/or the plakin family protein BP230 both of which are components 
      of hemidesmosomes in basal keratinocytes. Most BP autoantibodies particularly 
      target the epitopes within the non-collagenous NC16A domain of BP180. Clinical 
      findings and murine models of BP have provided evidence of a pathogenic role of 
      anti-NC16A autoantibodies. However, it is largely unknown what triggers the 
      breakage of immunotolerance against BP180 in elderly individuals. The incidence 
      of BP has been increased over the past two decades in several countries. Aside 
      from aging populations, the factors behind this phenomenon are still not fully 
      understood. Neurodegenerative diseases such as multiple sclerosis, Parkinson's 
      disease, and certain dementias are independent risk factors for BP. Recently 
      several case reports have described BP in patients with diabetes mellitus (DM) 
      patients who have been treated with dipeptidyl peptidase-4 inhibitors (DPP-4i or 
      gliptins), which are a widely used class of anti-DM drugs. The association 
      between the use of DPP-4is, particularly vildagliptin, and BP risk has been 
      confirmed by several epidemiological studies. Evidence suggests that cases of 
      gliptin-associated BP in Japan display certain features that set them apart from 
      cases of "regular" BP. These include a "non-inflammatory" phenotype, targeting by 
      antibodies of different immunodominant BP180 epitopes, and a specific association 
      with the human leukocyte antigen (HLA) types. However, recent studies in European 
      populations have found no major differences between the clinical and 
      immunological characteristics of gliptin-associated BP and "regular" BP. The 
      DPP-4 protein (also known as CD26) is ubiquitously expressed and has multiple 
      functions in various cell types. The different effects of the inhibition of 
      DPP-4/CD26 activity include, for example, tissue modeling and regulation of 
      inflammatory cells such as T lymphocytes. Although the pathomechanism of 
      gliptin-associated BP is currently largely unknown, investigation of the unique 
      effect of gliptins in the induction of BP may provide a novel route to better 
      understanding of how immunotolerance against BP180 breaks down in BP.
FAU - Tasanen, Kaisa
AU  - Tasanen K
AD  - PEDEGO Research Unit, Department of Dermatology, Medical Research Center Oulu, 
      Oulu University Hospital, University of Oulu, Oulu, Finland.
FAU - Varpuluoma, Outi
AU  - Varpuluoma O
AD  - PEDEGO Research Unit, Department of Dermatology, Medical Research Center Oulu, 
      Oulu University Hospital, University of Oulu, Oulu, Finland.
FAU - Nishie, Wataru
AU  - Nishie W
AD  - Department of Dermatology, Hokkaido University Graduate School of Medicine, 
      Sapporo, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20190604
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - EC 3.4.14.5 (DPP4 protein, human)
RN  - EC 3.4.14.5 (Dipeptidyl Peptidase 4)
RN  - I6B4B2U96P (Vildagliptin)
SB  - IM
CIN - Int J Dermatol. 2022 Aug;61(8):e310-e311. PMID: 34748212
MH  - Animals
MH  - Diabetes Mellitus/drug therapy
MH  - Dipeptidyl Peptidase 4/*metabolism
MH  - Dipeptidyl-Peptidase IV Inhibitors/*adverse effects/pharmacology
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/pharmacology
MH  - Japan
MH  - Pemphigoid, Bullous/*chemically induced/metabolism
MH  - Vildagliptin/adverse effects/pharmacology
PMC - PMC6593303
OTO - NOTNLM
OT  - BP180
OT  - CD26
OT  - DPP4
OT  - bullous pemphigoid
OT  - collagen XVII
OT  - diabetes mellitus
OT  - gliptins
EDAT- 2019/07/06 06:00
MHDA- 2020/10/23 06:00
PMCR- 2019/01/01
CRDT- 2019/07/06 06:00
PHST- 2019/04/01 00:00 [received]
PHST- 2019/05/16 00:00 [accepted]
PHST- 2019/07/06 06:00 [entrez]
PHST- 2019/07/06 06:00 [pubmed]
PHST- 2020/10/23 06:00 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2019.01238 [doi]
PST - epublish
SO  - Front Immunol. 2019 Jun 4;10:1238. doi: 10.3389/fimmu.2019.01238. eCollection 
      2019.